Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer

Authors

  • Giacomo Bregni Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Caroline Vandeputte GUTS Lab, Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Andrea Pretta Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Chiara Senti Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Elena Trevisi Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Elena Acedo Reina GUTS Lab, Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Pashalina Kehagias GUTS Lab, Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Gabriel Liberale Department of Surgery, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Luigi Moretti Department of Radiotherapy, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Maria Antonietta Bali Department of Radiology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Pieter Demetter Department of Pathology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Patrick Flamen Department of Nuclear Medicine, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Javier Carrasco Grand Hôpital de Charleroi, Charleroi, Belgium
  • Lionel D'Hondt CHU UCL Namur, Site Godinne, Yvoir, Belgium
  • Karen Geboes Department of Gastroenterology, Universitair Ziekenhuis Gent, Ghent, Belgium
  • Yeter Gokburun CHR Namur, Namur, Belgium
  • Marc Peeters Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium
  • Marc Van den Eynde Institut Roi Albert II, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium
  • Jean-Luc Van Laethem Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Philippe Vergauwe AZ Groeninge, Groeninge, Belgium
  • Camille Anastasia Chapot Clinical Trial Support Unit (CTSU), Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Marc Buyse International Drug Development Institute, Louvain-la-Neuve, Belgium
  • Amelie Deleporte Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Alain Hendlisz Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium
  • Francesco Sclafani Department of Medical Oncology, Institut Jules Bordet – Université Libre de Bruxelles (ULB), Brussels, Belgium

DOI:

https://doi.org/10.1080/0284186X.2020.1871067

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2021-04-03

How to Cite

Bregni, G., Vandeputte, C., Pretta, A., Senti, C., Trevisi, E., Acedo Reina, E., … Sclafani, F. (2021). Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. Acta Oncologica, 60(4), 549–553. https://doi.org/10.1080/0284186X.2020.1871067

Issue

Vol. 60 No. 4 (2021): Acta Oncologica

Section

Articles